Showing 3481-3490 of 18631 results for "".
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
https://reachmd.com/clinical-practice/oncology-hematology/adjuvant-pembrolizumab-plus-cisplatin-based-chemoradiation-in-locally-advanced-hnscc-first-results-from-the-randomized-phase-2b-adrisk-trial/39706/In the phase 2b ADRISK study, pembrolizumab added to adjuvant cisplatin-based chemoradiation did not significantly improve EFS or OS in locally advanced HNSCC.Potassium Binders in Practice: Clinical Trial Evidence
https://reachmd.com/programs/cme/tbd/37672/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.Stratifying Risk to Guide Therapy in R/R AML
https://reachmd.com/programs/cme/stratifying-risk-to-guide-therapy-in-rr-aml/36177/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer
https://reachmd.com/programs/cme/understanding-the-expanding-role-of-antibody-drug-conjugates-in-bladder-cancer/29173/This activity reviews the latest treatment guidelines for metastatic bladder cancer and emerging immunotherapies for muscle-invasive bladder cancer.Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
https://reachmd.com/programs/cme/expert-perspectives-on-nonsteroidal-mras-and-cardiorenal-protection/32990/Hear experts discuss the potential clinical implications of data in heart failure presented at the 2Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
https://reachmd.com/clinical-practice/oncology-hematology/patient-reported-outcomes-from-the-phase-3-keynote-689-trial-of-adding-perioperative-pembrolizumab-to-standard-of-care-in-resectable-locally-advanced-hnscc/39777/In KEYNOTE-689, patient-reported outcomes including HRQOL remained stable vs baseline with perioperative pembrolizumab in resectable locally advanced HNSCC.Potassium Binders: Safety Comes First!
https://reachmd.com/programs/cme/tbd/37673/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.Turmeric Tonic as a Treatment in Scalp Psoriasis
https://reachmd.com/programs/practical-dermatology-focus-psoriasis/turmeric-tonic-as-a-treatment-in-scalp-psoriasis/24460/Peter Lio, MD, leads this analysis of a study on the effectiveness of a topical turmeric preparation for mild-to-moderate scalp psoriasis. While the trial results indicated a reduction in Psoriasis Area & Severity Index (PASI) scores and improved quality of life for participants using the turmerKEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
https://reachmd.com/clinical-practice/oncology-hematology/keynote-717-randomized-phase-2-trial-of-adding-local-hypofractionated-radiotherapy-to-pembrolizumab-in-recurrent-or-metastatic-head-and-neck-cancer/39778/In the phase 2 KEYNOTE-717 trial, adding local hypofractionated radiotherapy to pembrolizumab improved systemic response rates in recurrent or metastatic HNSCC.Exosome Therapy for Pelvic Tissue Regeneration
https://modernaesthetics.com/ma-issues-index/september-october-2025/exosome-therapy-for-pelvic-tissue-regeneration/39268/Preclinical studies highlight potential applications for vaginal mesh complications, anal sphincter injury, and urinary incontinence